Multilevel determinants of HIV pre-exposure prophylaxis (PrEP) utilization and health disparities among Black and Hispanic women
|Dates:||9/1/2018 - 4/30/2022|
|Principal Investigator:||James M McMahon, PhD|
The use of antiretroviral medication—brand name Truvada—for the prevention of HIV (pre-exposure prophylaxis; PrEP) among Black and Latina women in the U.S. has the potential to significantly reduce disproportionately high rates of HIV in these groups. However, adoption of PrEP by women of color has been very limited, thereby reducing the public health benefit of PrEP to address racial and ethnic disparities in HIV transmission among women. The proposed study is designed to provide a knowledge base regarding key obstacles and facilitators of PrEP utilization that can be applied to develop effective PrEP interventions and delivery models for Black and Latina women.